Monthly Prescribing Reference6h
Use of Secondary CVD Prevention Medications Low in Most Countries
Use of one or more classes of medications for secondary CVD prevention peaked at 43.1 percent, decreased to 31.3 percent ...
thecardiologyadvisor.com7h
Novel PCSK9 Inhibitor Lerodalcibep Under Review for Patients Requiring LDL-C Reduction
The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.
Cancer Therapy Advisor17h
Adcetris Combo Approved for Rel/Ref Large B-Cell Lymphoma
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...
lupus.bmj1d
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.